Translating basic research into clinical rheumatology.
Findings from basic research in combination with precise clinical observations of the disease course in rheumatoid arthritis (RA) have led to the development of a multistage model to explain the pathophysiology of RA. Different cellular and soluble mediators, which play principal roles at different phases of the disease, have been identified. New therapeutic agents, which specifically target these factors, now allow us to intervene at several levels of the pathogenesis. This has already resulted in significant improvements for patients suffering from RA, and the development of new promising agents continues at a high pace. However, many questions concerning the optimal use of the new therapies remain unanswered. Combined efforts of basic research and clinical trials investigating the optimal timing and combination of the new treatments will be necessary to allow them to achieve their full potential and to result in the maximum benefit for patients.
van der Woude
D
D
Leiden University Medical Center, Department of Rheumatology, Albinusdreef 2, 2300 RC Leiden, The Netherlands. dvanderwoude@lumc.nl <dvanderwoude@lumc.nl>
Huizinga
T W J
TW
D018501:Antirheumatic Agents / Q000494:pharmacology*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000503:physiopathology*; D001323:Autoantibodies / Q000187:drug effects; D001402:B-Lymphocytes / Q000187:drug effects; D016207:Cytokines / Q000187:drug effects; D006801:Humans; D007113:Immunity, Innate / Q000187:drug effects; D007155:Immunologic Factors / Q000494:pharmacology*; D013601:T-Lymphocytes / Q000187:drug effects
D018501:Antirheumatic Agents; D001323:Autoantibodies; D016207:Cytokines; D007155:Immunologic Factors